Type of medical product:

Protein based





Indications for use:



Preclinical trials in vivo

As part of this project we are developing a bispecific monoclonal antibody that is directed to the effective attraction of the cytotoxic immune cells against human B-cell lymphomas. One part of this uniquely designed molecule would be able to recognize a B-cell marker that is present in a wide range of haematological malignancies, including acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL) and various types of non-Hodgkin’s lymphoma (NHL). The other part, the effector portion of this bi-specific antibody, would recognize a specific epitope of the receptor, located on the surface of the human cytotoxic T-lymphocytes.

Compare to other bispecific antibodies, our molecule possess a more potent tumor cells killing effect and have improved therapeutic properties. Implementation of this project will significantly increase the effectiveness of treatment of patients with different types of malignant B-cell tumours and will help those patients who are not responsive to the one of the most popular biologics — MabThera.

Our Partners:

  • The Foundation for Development of the Centre of Research and Commercializing of New Technologies — Skolkovo Foundation